• Don’t recommend radiation following hysterectomy for endometrial cancer patients with low-risk disease. Patients with low-risk endometrial cancer, including no residual disease in hysterectomy despite positive biopsy, grade 1 or 2 with <50 percent myometrial invasion and no additional high-risk features such as age >60, lymphovascular space invasion or cervical involvement have a very low risk of recurrence following surgery. …
• Don’t recommend radiation following hysterectomy for endometrial cancer patients with low-risk disease. Patients with low-risk endometrial cancer, including no residual disease in hysterectomy despite positive biopsy, grade 1 or 2 with <50 percent myometrial invasion and no additional high-risk features such as age >60, lymphovascular space invasion or cervical involvement have a very low risk of recurrence following surgery. Meta-analysis studies of radiation therapy for low-risk endometrial cancer demonstrate increased side effects with no benefit in overall survival compared with surgery alone. • Don’t routinely offer radiation therapy for patients who have resected non-small cell lung cancer (NSCLC), negative margins, N0-1 disease…
“Cancer relapses and treatment resistance have always been among the most daunting challenges in cancer care,” said press briefing moderator Gregory Masters, MD, FACP, ASCO Expert and a medical oncologist at the Helen F. Graham Cancer Center in Newark, Delaware. “The good news is that genomic medicine is helping to overcome these challenges by revealing new ways to target a cancer cell’s inner workings. …
source : http://www.sciencedaily.com/releases/2014/05/140518164419.htm
In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall survival than has been seen historically with such patients receiving standard preventive therapy, the investigators reported at the American Society of Hematology annual meeting. …